SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs upcoming decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders citing the amended upper-limb data, rare-disease policy discussions and recent launch-related hiring as reasons for optimism. Others caution that approval is uncertain given the prior negative review and continuing questions about the evidence.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens strong quarterly results and rapid PAPZIMEOS commercial uptake are driving attention, with traders highlighting the companys return to profitability and potential for further growth. The upbeat reaction is accompanied by short-squeeze speculation and interest in upcoming PRGN-2009 data and European expansion.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a 52-week high has traders positioning around the expected Q3 earnings report, with BRIUMVIs sales growth supporting optimism. Buyout rumors and heavy short interest are fueling squeeze speculation, though some traders see earnings expectationsnot a confirmed acquisitionas the main driver.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths post-TDAPA Medicare add-on could fall sharply after Q1 2027 has fueled concerns about pricing and CorMedix revenue amid a steep selloff. Traders dispute whether DaVitas preliminary outlook signals a broader reimbursement decline, pointing to CMSs published estimate, while others criticize management for not clarifying the potential impact.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL leukemia trial reached its prespecified 80th death event, triggering final analysis and putting the GPS survival readout at the center of discussion. Traders are divided between optimism about a strong result and concerns about the control arm and trial design, while shares have come under pressure ahead of the binary catalyst.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure after a steep decline, with traders focused on analyst price-target cuts and uncertainty ahead of its earnings report, as well as concerns about digital-ad growth. Bulls argue the selloff is disconnected from the companys profitability and growth, while bears warn of more downside if results or guidance disappoint; some also point to broader tech-market weakness.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp technology and AI-linked selloffintensified by Intels weak outlook and concerns about returns on heavy AI investmentis driving attention to QQQ. Traders are split between warning of more downside and treating the drop as an oversold dip with potential for a rebound.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure amid a semiconductor and tech selloff, as traders question whether heavy AI infrastructure spending will generate adequate returns; weak Intel guidance and concerns about Amazons elevated capex are cited as contributing pressures. The community is divided between expecting a deeper unwind in the AI trade and seeing oversold conditions and technical support as possible grounds for a bounce.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas strong quarterly results and raised outlook, alongside expectations that AI agents will increase demand for identity security, fueled a sharp rally. Traders are now debating whether the growth outlook justifies the valuation, with some taking profits or positioning for a pullback.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, supported by growth in Eylea HD and Sanofi collaboration revenue from Dupixent, drove a sharp share-price gain. Traders largely celebrated the earnings beat and breakout, while some pointed to the upcoming cemdisiran decision as another potential catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Twist Bioscience Launches MRD Express with Rapid Turnaround Time

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched Twist MRD Express, custom panels manufactured at scale with a rapid turnaround time starting within one day. Twist MRD Express custom panels enable cancer researchers to investigate...

Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodies

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its antibody production and characterization portfolio with the launch of Twist Express Screening Antibodies, a high-throughput cell-free offering that delivers purified full-length IgG with SPR...

Twist Bioscience to Report Fiscal 2026 Fourth Quarter and Full Year Financial Results on Thursday, November 12, 2026

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced that it will issue its financial results for the fiscal 2026 fourth quarter and full year ended September 30, 2026, before the opening of the market on November 12, 2026. The company plans to...

Cathie Wood-Led Ark Invest's Biggest Q3 Winners And Losers — PLTR, NVDA, TXG Led While TSLA, RKLB Dragged

Equity

Ark's latest quarterly report shows that several stocks made meaningful contributions across multiple ETFs.

Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares

Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.


$1000 Invested In Twist Bioscience 5 Years Ago Would Be Worth This Much Today

Twist Bioscience (NASDAQ:TWST) has outperformed the market over the past 5 years by 3.68% on an annualized basis producing an average annual return of 15.78%. Currently, Twist Bioscience has a market capitalization ofread more...

Cathie Wood’s ARKG Is Crushing Her Other ETFs: 2 Biotech Bets Have Surged Nearly 6X This Year 

Twist’s Lilly agreement and involvement in Anthropic research highlight its role in building and testing AI-designed proteins.

AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment

AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment AI Drug Discovery Forecasts Vary Widely as Sector Shifts to DeploymentPR NewswireAUSTIN, Texas, Oct. 1, 2026Equity Insider News CommentaryAUSTIN, Texas, Oct. 1, 2026 /PRNewswire/ --Towards Healthcare projects that the global AI...

Biotech And Biomimicry Stocks Lighting Up the Market

Biotech and life-science stocks are commanding attention as a fresh wave of momentum sweeps through the sector, with Silexion Therapeutics (NASDAQ:SLXN), Kraig Biocraft Laboratories (OTCQB:KBLB), 10x Genomics (NASDAQ:TXG), Moderna (NASDAQ:MRNA), AbCellera Biologics (NASDAQ:ABCL), Viatris (NASDAQ:VTRS), and Twist Bioscience (NASDAQ:TWST) among today’s notable names.

Twist Bioscience Stock Hits New High, Then Retreats: What's Happening?

Twist Bioscience shares are trading lower Friday, pulling back after touching a fresh 52-week high near $192 earlier in the session.read more...

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Twist Bioscience Corp

Bullish Sentiment

<ul class="summary-bullets"><li>10x Genomics and Palantir were among the standout winners across Ark's portfolios.</li><li>Ark attributed the 10x Genomics rally to growing interest in single-cell sequencing and spatial analysis as sources of data for AI drug-discovery models.</li><li>Nvidia also made the cut, particularly across Ark's technology-focused portfolios.</li></ul>Cathie Wood-led Ark Invest's portfolios saw some dramatic winners and losers in the third quarter (Q3), with artificial intelligence, biotech, crypto and other disruptive-technology bets among the biggest drivers.Ark's latest quarterly report shows that several stocks made meaningful contributions across multiple ETFs, while Tesla Inc. (TSLA) and Rocket Lab Corp. (RKLB) emerged among the most notable drags. Ark's attribution figures measure each holding's contribution to its ETF's performance, rather than the stock's standalone return.<h2 class="st-heading-2">Ark’s Biggest Winners In Q3</h2>10x Genomics Inc. (TXG) was the standout winner across Ark's portfolios. The stock contributed 9.03 percentage points to ARK Genomic Revolution ETF’s (ARKG) 28.92% Q3 gain and 2.92 points to ARK Innovation ETF’s (ARKK) 10.39% return during the quarter.Ark attributed the rally to growing interest in single-cell sequencing and spatial analysis as sources of data for AI drug-discovery models. The firm also highlighted the launch of 10x's Atera spatial system, with orders already in place for the 40 shipments anticipated in 2026.Twist Bioscience Corp. (TWST) was another major biotech winner, contributing 6.51 points to ARKG and 2.55 points to ARKK. The stock jumped 87.83% during the quarter. Ark said Twist was increasingly recognized as a beneficiary of AI-driven drug discovery, including through its protein-characterization work for Anthropic.&nbsp;Tempus AI Inc. (TEM) also stood out, contributing 3.21 points to ARKG and 2.08 points to ARKK, while gaining 41.38% during the quarter.&nbsp;Then there was Palantir Technologies Inc. (PLTR), emerging as one of the most important cross-ETF winners. Palantir contributed 1.86 points to ARK Autonomous Technology &amp; Robotics ETF (ARKQ), 1.62 points to ARKK, 1.48 points to ARK Next Generation Technology ETF (ARKW), 2.39 points to ARK Blockchain &amp; Fintech Innovation ETF (ARKF) and 1.47 points to ARK Space &amp; Defense Innovation ETF (ARKX).Nvidia Corp. (NVDA) also made the cut, particularly across Ark's technology-focused portfolios. It contributed 0.49 points to ARKQ and 0.48 points to ARKX.<h2 class="st-heading-2">Biggest Losers</h2>Tesla was the clearest recurring drag across Ark's portfolios. It was the biggest detractor in ARKQ (-1.72 percentage points), ARKK (-1.75 points) and ARKW (-1.43 points).Ark said Tesla sold off sharply after its second-quarter (Q2) results disappointed on profitability, with price cuts and the wind-down of the Model S and Model X pressuring margins.But the firm also pointed to a recovery in the stock as Tesla publicly launched Cybercab in Austin and surpassed 1 million unsupervised robotaxi miles, up from 380,000 just six weeks earlier.Rocket Lab was another major drag, particularly in the space-focused portfolios. It contributed -1.39 points to ARKQ and -2.04 points to ARKX.The firm noted that Rocket Lab completed 21 flights in 2025 and had a backlog of more than 90 missions as of the second quarter.Ark's biggest winners included AI, AI-enabled biotech and other technology bets, while some of its highest-profile holdings, most notably Tesla and Rocket Lab, weighed on performance.<a href="https://stocktwits.com/symbol/ARKK">ARKK ETF</a> declined nearly 5% in Friday’s regular trading session and fell nearly 0.4% during the after-hours trade. Retail sentiment on Stocktwits around ARKK trended in the ‘bearish’ territory at the time of writing.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-denies-spacex-starlink-slowed-down-white-house-elon-musk/cZxkR3ARBtB">Trump Denies SpaceX’s Starlink Was Slowed Down Over Ukraine By Either White House Or Elon Musk: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cathie Wood, chief executive officer and chief investment officer, Ark Invest, gestures as she speaks during the Bitcoin 2022 Conference at Miami Beach Convention Center on April 7, 2022. (Photo by Marco Bello/Getty Images)

Cathie Wood-Led Ark Invest's Biggest Q3 Winners and Losers — PLTR, NVDA, TXG Led While TSLA, RKLB Dragged

ARK Fintech Innovation ETF

ARK Investment Management LLC - ARK Genomic Revolution ETF

ARK Innovation ETF

ARK Next Generation Internet ETF

ARK Space Exploration & Innovation ETF

Palantir Technologies Inc

Rocket Lab USA Inc

Tempus AI Inc

10x Genomics Inc - Ordinary Shares - Class A

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$152.78
Prev Close	$173.45
Open	$162.94
Dividend Yield	0.00%
50-Day Moving Average	$152.78
Beta	2.29
Avg. Volume	2.15M
PE Ratio	-78.00

52-Week High	$219.71
52-Week Low	$23.30
Market Capitalization	$11.42B
EPS (Annual)	-$1.30
Price to Book	24.39
Revenue Per Employee	$384,649.64

Feed

News

Sentiment

Earnings

Fundamentals

Info

TWST Fundamentals